We report a case of immunotherapy associated myopericarditis in a
patient treated with Nivolumab/Ipilimumab. We furthermore performed a
comprehensive literature review regarding the biological mechanisms of
cancer immunity, the pathophysiology behind immunotherapy related
adverse effects (irAEs), current guideline, and the role of immune
checkpoint inhibitors to the recurrent irAEs.